Histogen (FRA:CPH) Treasury Stock : €0.00 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Histogen's treasury stock for the quarter that ended in Sep. 2023 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Histogen Treasury Stock Historical Data

The historical data trend for Histogen's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Treasury Stock Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Treasury Stock

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Treasury Stock	Get a 7-Day Free Trial													-	-	-	-	-

Histogen Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Histogen (FRA:CPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

HSTO:USA

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines